A clinical study of adenovirus mediated Reduced Expression in Immortalized Cells/Dickkopf-3 (REIC/Dkk-3) gene therapy for malignant pleural mesothelioma - Malignant pleural mesothelioma gene therapy using REIC

Okayama University Hospital0 个研究点目标入组 24 人开始时间: 2014年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients with poor-controlled systemic disease 2)Patients with active infections 3)Patients with active double cancer 4)Patients with brain metastasis 5)Patients with interstitial pneumonia or lung fibrosis detected by CXR 6)Patients with recurrent malignant pleural mesothelioma after extrapleural pneumonenctomy or Patients with pneumonectomy due to the disease other than malignant pleural mesothelioma 7)Patients with cardiac effusion requiring the treatment 8)Patients more than 1:1000 titer of neutralizing antibody for adenovirus 9)Patients injected with unapproved drugs within 4 weeks 10) Pregnant or breast-feeding females and females who have a possibility of pregnancy or lactation or patients who does not intend to use birth control 11) Patients who can not use contraception for 90 days after the final administration of REIC 12) Other patients judged to be ineligible by the investigator

发起方